I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients


Trial ID: NCT04488081


The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

Official Title

I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients

Stanford Investigator(s)

Joseph Levitt, MD, MS
Joseph Levitt, MD, MS

Associate Professor of Medicine (Pulmonary and Critical Care Medicine)


Inclusion Criteria:

A. Male or Female, at least 18 years old.

B. Admitted to the hospital and placed on high flow oxygen (greater than 6L by nasal
cannula or mask delivery system) or intubated for the treatment of (established or
presumed) COVID-19.

C. Informed consent provided by the patient or health care proxy.

D. Confirmation of SARS-CoV-2 infection by PCR or Rapid antigen testing for SARS-CoV-2
infection prior to randomization.

Exclusion Criteria:

A. Pregnant or breastfeeding women (must be documented by a pregnancy test during

B. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to study agent based on review of the medical record and patient history.

C. Comfort measures only.

D. Acute liver disease, or chronic liver disease with a Child-Pugh score greater than 11.

E. Resident for more than six months at a skilled nursing facility.

F. Estimated mortality greater than 50% over the next six months from underlying chronic

G. Time since requirement for high flow oxygen or ventilation greater than 5 days.

H. Anticipated transfer to another hospital which is not a study site within 72 hours.

I. Patients with either end-stage kidney disease or acute kidney injury who are on

J. Co-enrollment in clinical trials of pharmacologic agents requiring an IND

K. On 3 or more vasopressors

L. Pre-existing heart failure with a known left ventricular ejection fraction <25% or
unstable angina pectoris


drug: Remdesivir

drug: Cyclosporine

drug: Imatinib Mesylate

drug: Dexamethasone

drug: Cenicriviroc

drug: Icatibant

drug: Apremilast

biological: dornase alfa

drug: Celecoxib

drug: Famotidine

biological: IC14

drug: Aviptadil

biological: narsoplimab

drug: Cyproheptadine


Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305